The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Muhammad Wasif Saif

Yale University School of Medicine

Section of Medical Oncology

New Haven

Connecticut 06520

USA

[email]@yale.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Yale University School of Medicine, Section of Medical Oncology, New Haven, Connecticut 06520, USA. 2005 - 2010
  • Gastrointestinal Cancers Program, Yale Cancer Center, and Yale University School of Medicine, New Haven, USA. 2010
  • Division of Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, USA. 2010
  • Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, USA. 2005 - 2007

References

  1. Role and cost effectiveness of PET/CT in management of patients with cancer. Saif, M.W., Tzannou, I., Makrilia, N., Syrigos, K. Yale. J. Biol. Med (2010) [Pubmed]
  2. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Saif, M.W., Gnanaraj, J. Cutan. Ocul. Toxicol (2010) [Pubmed]
  3. Biology of colorectal cancer. Saif, M.W., Chu, E. Cancer. J (2010) [Pubmed]
  4. Colorectal cancer in review: the role of the EGFR pathway. Saif, M.W. Expert. Opin. Investig. Drugs (2010) [Pubmed]
  5. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Li, J., Merl, M., Lee, M.X., Kaley, K., Saif, M.W. Expert. Opin. Drug. Saf (2010) [Pubmed]
  6. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Saif, M.W., Sellers, S., Diasio, R.B., Douillard, J.Y. Anticancer. Drugs (2010) [Pubmed]
  7. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Saif, M.W., Syrigos, K., Kaley, K., Isufi, I. Anticancer Res. (2010) [Pubmed]
  8. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Saif, M.W., Syrigos, K., Penney, R., Kaley, K. Anticancer Res. (2010) [Pubmed]
  9. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Saif, M.W., Lansigan, F., Ruta, S., Lamb, L., Mezes, M., Elligers, K., Grant, N., Jiang, Z.L., Liu, S.H., Cheng, Y.C. Phytomedicine (2010) [Pubmed]
  10. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Saif, M.W., Podoltsev, N.A., Rubin, M.S., Figueroa, J.A., Lee, M.Y., Kwon, J., Rowen, E., Yu, J., Kerr, R.O. Cancer Invest. (2010) [Pubmed]
  11. Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. Saif, M.W., Kaley, K., Lamb, L., Pecerillo, J., Hotchkiss, S., Steven, L., Brennan, M., Penney, R., Gillespie, C., Shaib, W. JOP (2010) [Pubmed]
  12. Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. Bussom, S., Saif, M.W. JOP (2010) [Pubmed]
  13. Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. Bussom, S., Saif, M.W. JOP (2010) [Pubmed]
  14. Fluoropyrimidine-associated cardiotoxicity: revisited. Saif, M.W., Shah, M.M., Shah, A.R. Expert. Opin. Drug. Saf (2009) [Pubmed]
  15. K-ras mutations in colorectal cancer: a practice changing discovery. Saif, M.W., Shah, M. Clin. Adv. Hematol. Oncol (2009) [Pubmed]
  16. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Saif, M.W., Peccerillo, J., Potter, V. Cancer Chemother. Pharmacol. (2009) [Pubmed]
  17. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Saif, M.W., Hashmi, S., Bell, D., Diasio, R.B. Expert. Opin. Drug. Saf (2009) [Pubmed]
  18. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Saif, M.W., Syrigos, K.I., Hotchkiss, S., Shanley, J., Grasso, J., Ferencz, T.M., Syrigos, K., Shah, M.M. Cancer Chemother. Pharmacol. (2009) [Pubmed]
  19. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. Saif, M.W. World J. Gastroenterol. (2009) [Pubmed]
  20. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Saif, M.W., Oettle, H., Vervenne, W.L., Thomas, J.P., Spitzer, G., Visseren-Grul, C., Enas, N., Richards, D.A. Cancer. J (2009) [Pubmed]
  21. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. Saif, M.W., Shi, N., Zelt, S. World J. Gastroenterol. (2009) [Pubmed]
  22. S-1: a promising new oral fluoropyrimidine derivative. Saif, M.W., Syrigos, K.N., Katirtzoglou, N.A. Expert. Opin. Investig. Drugs (2009) [Pubmed]
  23. Chemotherapy options and outcomes in older adult patients with colorectal cancer. Saif, M.W., Lichtman, S.M. Crit. Rev. Oncol. Hematol. (2009) [Pubmed]
  24. Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. Saif, M.W. JOP (2009) [Pubmed]
  25. Management of ascites due to gastrointestinal malignancy. Saif, M.W., Siddiqui, I.A., Sohail, M.A. Ann. Saudi. Med (2009) [Pubmed]
  26. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. Saif, M.W., Choma, A., Salamone, S.J., Chu, E. J. Natl. Cancer Inst. (2009) [Pubmed]
  27. Variant Hypersensitivity Reaction (HSR) Presented with Persistent Dry Cough after Receiving Oxaliplatin in a Pancreatic Cancer Patient. Li, J., Peccerillo, J., Kaley, K., Saif, M.W. Iran. J. Allergy. Asthma. Immunol (2009) [Pubmed]
  28. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Saif, M.W., Longo, W.L., Israel, G. Clin. Colorectal. Cancer (2008) [Pubmed]
  29. Capecitabine-related cardiotoxicity: recognition and management. Saif, M.W., Tomita, M., Ledbetter, L., Diasio, R.B. J. Support. Oncol (2008) [Pubmed]
  30. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Saif, M.W., Hashmi, S., Zelterman, D., Almhanna, K., Kim, R. Int. J. Colorectal. Dis (2008) [Pubmed]
  31. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. Saif, M.W., Merikas, I., Tsimboukis, S., Syrigos, K. JOP (2008) [Pubmed]
  32. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Saif, M.W., Hashmi, S. Cancer Chemother. Pharmacol. (2008) [Pubmed]
  33. Erlotinib: the first biologic in the management of pancreatic cancer. Saif, M.W. Expert. Opin. Pharmacother (2008) [Pubmed]
  34. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008. Saif, M.W. JOP (2008) [Pubmed]
  35. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Saif, M.W. Clin. Adv. Hematol. Oncol (2008) [Pubmed]
  36. Capecitabine: an overview of the side effects and their management. Saif, M.W., Katirtzoglou, N.A., Syrigos, K.N. Anticancer. Drugs (2008) [Pubmed]
  37. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. Saif, M.W., Cornfeld, D., Modarresifar, H., Ojha, B. J. Gastrointestin. Liver. Dis (2008) [Pubmed]
  38. Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. Saif, M.W. JOP (2008) [Pubmed]
  39. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? Saif, M.W., Sandoval, A. Cutan. Ocul. Toxicol (2008) [Pubmed]
  40. New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. Saif, M.W. JOP (2008) [Pubmed]
  41. Management of hypomagnesemia in cancer patients receiving chemotherapy. Saif, M.W. J. Support. Oncol (2008) [Pubmed]
  42. Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. Saif, M.W. JOP (2008) [Pubmed]
  43. Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction. Saif, M.W., Roy, S., Ledbetter, L., Madison, J., Syrigos, K. World J. Gastroenterol. (2007) [Pubmed]
  44. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Saif, M.W., Sellers, S., Li, M., Wang, W., Cusimano, L., Wang, H., Zhang, R. Cancer Chemother. Pharmacol. (2007) [Pubmed]
  45. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Saif, M.W., Ezzeldin, H., Vance, K., Sellers, S., Diasio, R.B. Cancer Chemother. Pharmacol. (2007) [Pubmed]
  46. Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007. Saif, M.W. JOP (2007) [Pubmed]
  47. Role of platinum agents in the management of advanced pancreatic cancer. Saif, M.W., Kim, R. Expert. Opin. Pharmacother (2007) [Pubmed]
  48. Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis. Saif, M.W., Khubchandani, S., Walczak, M. World J. Gastroenterol. (2007) [Pubmed]
  49. IPdR: a novel oral radiosensitizer. Saif, M.W., Berk, G., Cheng, Y.C., Kinsella, T.J. Expert. Opin. Investig. Drugs (2007) [Pubmed]
  50. Safety of capecitabine use in patients with liver dysfunction. Saif, M.W., Tejani, M.A. Clin. Adv. Hematol. Oncol (2007) [Pubmed]
  51. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Saif, M.W., Black, G., Roy, S., Bell, D., Russo, S., Eloubeidi, M.A., Steg, A., Johnson, M.R., Zelterman, D., Diasio, R.B. Cancer. J (2007) [Pubmed]
  52. Pancreatoblastoma. Saif, M.W. JOP (2007) [Pubmed]
  53. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Saif, M.W., Elfiky, A., Salem, R.R. Ann. Surg. Oncol. (2007) [Pubmed]
  54. Incidence and management of cutaneous toxicities associated with cetuximab. Saif, M.W., Kim, R. Expert. Opin. Drug. Saf (2007) [Pubmed]
  55. The clinical significance of autoantibodies in gastrointestinal malignancies: an overview. Saif, M.W., Zalonis, A., Syrigos, K. Expert. Opin. Biol. Ther (2007) [Pubmed]
  56. Genetic alterations in pancreatic cancer. Saif, M.W., Karapanagiotou, L., Syrigos, K. World J. Gastroenterol. (2007) [Pubmed]
  57. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Saif, M.W., Kang, S.P., Chu, E. Oncology (Williston Park, N.Y.) (2006) [Pubmed]
  58. Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Saif, M.W., Hashmi, S., Mattison, L., Donovan, W.B., Diasio, R.B. Anticancer. Drugs (2006) [Pubmed]
  59. Gemcitabine-related radiation recall in a patient with pancreatic cancer. Saif, M.W., Sellers, S., Russo, S. Anticancer. Drugs (2006) [Pubmed]
  60. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Saif, M.W., Mattison, L., Carollo, T., Ezzeldin, H., Diasio, R.B. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  61. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?. Saif, M.W., Diasio, R. Clin. Colorectal. Cancer (2006) [Pubmed]
  62. Anti-angiogenesis therapy in pancreatic carcinoma. Saif, M.W. JOP (2006) [Pubmed]
  63. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Saif, M.W., Black, G., Johnson, M., Russo, S., Diasio, R. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  64. Primary pancreatic lymphomas. Saif, M.W. JOP (2006) [Pubmed]
  65. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Saif, M.W., Mehra, R. Expert. Opin. Drug. Saf (2006) [Pubmed]
  66. Targeted agents for adjuvant therapy of colon cancer. Saif, M.W. Clin. Colorectal. Cancer (2006) [Pubmed]
  67. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006. Saif, M.W. JOP (2006) [Pubmed]
  68. Hypersensitivity reactions associated with oxaliplatin. Saif, M.W. Expert. Opin. Drug. Saf (2006) [Pubmed]
  69. Role of panitumumab in the management of metastatic colorectal cancer. Saif, M.W., Cohenuram, M. Clin. Colorectal. Cancer (2006) [Pubmed]
  70. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Saif, M.W., Elfiky, A., Diasio, R. Clin. Colorectal. Cancer (2006) [Pubmed]
  71. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma. Saif, M.W., Merritt, J., Robbins, J., Stewart, J., Schupp, J. Clin. Colorectal. Cancer (2006) [Pubmed]
  72. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Saif, M.W. Clin. Colorectal. Cancer (2005) [Pubmed]
  73. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. Saif, M.W., Eloubeidi, M.A., Russo, S., Steg, A., Thornton, J., Fiveash, J., Carpenter, M., Blanquicett, C., Diasio, R.B., Johnson, M.R. J. Clin. Oncol. (2005) [Pubmed]
  74. Management of colorectal cancer in pregnancy: a multimodality approach. Saif, M.W. Clin. Colorectal. Cancer (2005) [Pubmed]
 
WikiGenes - Universities